US › Healthcare

CNS Pharmaceuticals Inc (CNSP)

US · Healthcare · Biotechnology

$5.36-7.43%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-4.9M
Profit YoY
-14.8%
EPS
$-10.15
EPS estimate
$-5.09

EPS came in at -10.15 against a street estimate of -5.09 — a miss of 99.4%.

Key statistics

Market cap
$7.3M
Forward P/E
0.0
P/B
104.80
Book value
$0.09
EPS (TTM)
$-23.79
52-week high
$10.59
52-week low
$1.90
50-day MA
$4.92
200-day MA
$5.14
Beta
1.02

Analyst view

Analysts rate CNS Pharmaceuticals Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $10.00.

Shareholding

Insiders
0.49%
Institutions
12.51%

Largest institutional holders

FundStake
Stonepine Capital Management Llc4.17%
Ikarian Capital, LLC3.14%
Geode Capital Management, LLC1.59%
BOOTHBAY FUND MANAGEMENT, LLC0.93%
Tower Research Capital LLC0.09%
UBS Group AG0.05%
BARRETT & COMPANY, INC.0.00%
Mccormack Advisors International0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CNS Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.